Rani Therapeutics (RANI) Competitors

Rani Therapeutics logo
$1.67 +0.26 (+18.44%)
As of 03:39 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

RANI vs. ATAI, KOD, RZLT, NMRA, ATYR, EYEN, ENGN, CMPS, VYGR, and BTMD

Should you be buying Rani Therapeutics stock or one of its competitors? The main competitors of Rani Therapeutics include Atai Life Sciences (ATAI), Kodiak Sciences (KOD), Rezolute (RZLT), Neumora Therapeutics (NMRA), Atyr PHARMA (ATYR), Eyenovia (EYEN), enGene (ENGN), COMPASS Pathways (CMPS), Voyager Therapeutics (VYGR), and biote (BTMD). These companies are all part of the "pharmaceutical products" industry.

Rani Therapeutics vs.

Rani Therapeutics (NASDAQ:RANI) and Atai Life Sciences (NASDAQ:ATAI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings, risk and community ranking.

In the previous week, Rani Therapeutics had 4 more articles in the media than Atai Life Sciences. MarketBeat recorded 9 mentions for Rani Therapeutics and 5 mentions for Atai Life Sciences. Atai Life Sciences' average media sentiment score of 0.84 beat Rani Therapeutics' score of 0.50 indicating that Atai Life Sciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Rani Therapeutics
3 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Atai Life Sciences
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Atai Life Sciences received 300 more outperform votes than Rani Therapeutics when rated by MarketBeat users. However, 82.05% of users gave Rani Therapeutics an outperform vote while only 66.40% of users gave Atai Life Sciences an outperform vote.

CompanyUnderperformOutperform
Rani TherapeuticsOutperform Votes
32
82.05%
Underperform Votes
7
17.95%
Atai Life SciencesOutperform Votes
332
66.40%
Underperform Votes
168
33.60%

Rani Therapeutics has a beta of 0.16, indicating that its share price is 84% less volatile than the S&P 500. Comparatively, Atai Life Sciences has a beta of 1.22, indicating that its share price is 22% more volatile than the S&P 500.

Rani Therapeutics has higher earnings, but lower revenue than Atai Life Sciences. Atai Life Sciences is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rani TherapeuticsN/AN/A-$33.97M-$1.06-1.33
Atai Life Sciences$310K1,207.08-$40.22M-$0.81-2.75

30.2% of Rani Therapeutics shares are held by institutional investors. Comparatively, 28.4% of Atai Life Sciences shares are held by institutional investors. 53.3% of Rani Therapeutics shares are held by insiders. Comparatively, 31.2% of Atai Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Atai Life Sciences' return on equity of -65.75% beat Rani Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Rani TherapeuticsN/A -219.64% -56.71%
Atai Life Sciences N/A -65.75%-52.71%

Rani Therapeutics presently has a consensus target price of $12.33, indicating a potential upside of 774.70%. Atai Life Sciences has a consensus target price of $9.00, indicating a potential upside of 303.59%. Given Rani Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Rani Therapeutics is more favorable than Atai Life Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rani Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.17
Atai Life Sciences
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Rani Therapeutics beats Atai Life Sciences on 10 of the 17 factors compared between the two stocks.

Get Rani Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RANI and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RANI vs. The Competition

MetricRani TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$94.53M$7.01B$5.77B$9.15B
Dividend YieldN/A2.91%5.30%4.00%
P/E Ratio-1.334.7663.0615.55
Price / SalesN/A308.111,052.0475.78
Price / CashN/A75.4646.0938.87
Price / Book2.765.535.074.99
Net Income-$33.97M$123.50M$113.45M$222.61M
7 Day Performance-2.08%-4.71%-1.89%-0.88%
1 Month Performance12.80%-1.95%3.22%2.62%
1 Year Performance-60.50%2.29%21.03%17.59%

Rani Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RANI
Rani Therapeutics
3.5732 of 5 stars
$1.67
+18.5%
$12.33
+638.1%
-62.8%$94.82MN/A-1.56110Gap Up
ATAI
Atai Life Sciences
2.7201 of 5 stars
$1.85
+19.4%
$9.00
+386.5%
+28.9%$310.43M$310,000.00-2.2880High Trading Volume
KOD
Kodiak Sciences
4.2752 of 5 stars
$5.82
-9.1%
$8.00
+37.5%
-0.7%$306.25MN/A-1.5990Short Interest ↑
Positive News
Gap Down
RZLT
Rezolute
3.3892 of 5 stars
$5.24
-0.2%
$24.13
+360.4%
+350.9%$303.62MN/A-4.1340Analyst Forecast
Short Interest ↑
NMRA
Neumora Therapeutics
4.0282 of 5 stars
$1.86
-3.6%
$16.50
+787.1%
-90.9%$300.50MN/A-0.99108News Coverage
ATYR
Atyr PHARMA
2.5517 of 5 stars
$3.57
-7.5%
$19.25
+439.2%
N/A$299.67M$350,000.00-3.8053Short Interest ↑
EYEN
Eyenovia
1.0633 of 5 stars
$2.68
-3.2%
$160.00
+5,870.1%
-98.8%$298.62M$31,832.00-3.6740Short Interest ↓
Analyst Revision
Gap Down
ENGN
enGene
3.2023 of 5 stars
$6.69
-0.1%
$29.78
+345.1%
-20.3%$295.81MN/A-11.5331Short Interest ↓
CMPS
COMPASS Pathways
1.9116 of 5 stars
$4.31
flat
$33.60
+679.6%
-60.2%$294.89MN/A-1.96120
VYGR
Voyager Therapeutics
4.7849 of 5 stars
$5.33
-2.2%
$15.97
+199.6%
-44.7%$291.18M$250.01M7.51100Analyst Forecast
News Coverage
BTMD
biote
3.4351 of 5 stars
$5.29
+3.9%
$10.00
+89.0%
+23.1%$287.46M$185.36M20.35194Short Interest ↓

Related Companies and Tools


This page (NASDAQ:RANI) was last updated on 2/12/2025 by MarketBeat.com Staff
From Our Partners